A Phase 1, Multicenter, Open-label, First-in-human, Dose Escalation and Expansion Study of DM005 in Patients With Advanced Solid Tumors
Latest Information Update: 21 Jan 2025
At a glance
- Drugs DM 005 (Primary)
- Indications Colorectal cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Doma BioPharmaceutical
Most Recent Events
- 15 Jan 2025 Planned primary completion date changed from 1 Sep 2026 to 1 Oct 2026.
- 15 Jan 2025 Status changed from not yet recruiting to recruiting.
- 26 Jul 2024 New trial record